Net Income

Delcath Systems is set to showcase its innovative HEPZATO KIT at SIR 2026, signaling growing adoption and a pivotal moment for its targeted cancer therapy.

The tech firm posts impressive growth from defense and EV sectors, but a 'going concern' notice in its annual report reveals significant liquidity challenges.

With its pure-play chemical transition complete, Ascent adds two heavyweights to its board, signaling an aggressive new phase of growth and M&A.

Fed Governor Michael Barr's keynote at EMERGE 2026 signals a new regulatory focus on AI, data, and the economic realities facing American households.

With a key data readout looming for its chronic cough drug, Nocion adds a renowned dealmaker to its board, fueling speculation of a potential acquisition.

With a unique drug that preserves muscle while shedding fat, a newly fortified biotech is set to challenge the titans of the weight-loss market.

With the appointment of Stephen Gilderdale, Senzing signals its ambition to dominate the critical data trust layer for a new generation of autonomous AI.

A new CMS pilot program allows CBD for Medicare patients at no cost, sparking a race among suppliers like High Tide's NuLeaf Naturals to enter the market.

Canals' new end-to-end AI platform promises radical efficiency for distributors. But what are the real-world impacts on jobs, data, and integration?

TRIMEDX's repeat recognition as an inspiring workplace signals a strategic advantage, proving a 'PeopleFirst' culture is vital in the competitive MedTech sector.

For 30 years, a nonprofit has awarded millions in educational aid. See how Alliance Direct Benefits’ unique membership model is shaping student futures.

Amid a global uranium rush, Traction Uranium secures a key property in Saskatchewan. But can the junior explorer turn geological promise into shareholder value?

A new investigation shows drug companies make $31 in profit for every $1 paid in penalties, suggesting fines are just a cost of doing business.

As Stryker preps its Q1 2026 report, all eyes are on whether the MedTech giant can sustain its momentum amid new products and industry-wide pressures.

Nexera Technologies reports 23% revenue growth while executing a bold strategic shift from online retail to the high-stakes AI homeland security market.

Following its major Vistance CCS acquisition, Amphenol launches a mandatory open offer for ADC India, deepening its hold on a key global growth market.

In a tough biotech market, NewcelX's $1.35M financing at a 30% premium signals strong confidence in its pioneering stem cell therapy for Type 1 Diabetes.

With a new CEO, full ownership of BGO and Crescent, and a bold equity plan, SLC Management is pivoting from acquisitions to integrated platform growth.

With Governor Polis proclaiming April Safe Digging Month, officials warn that a simple call to 811 is crucial to prevent costly and dangerous utility strikes.

Facing Nasdaq delisting, Chinese IT firm Hitek Global enacts a massive reverse stock split. Is this a strategic reset or a desperate last stand for survival?